These clinical studies clearly demonstrate that although not all Type 2 diabetes patients benefit from Imatinib therapy, there is a substantial proportion that responds, and some cases so dramatically that they become insulin-independent. The gene discussed is INS; the disease is type 2 diabetes mellitus.